IL318758A - Anti cancer combinations comprising chemotherapy - Google Patents
Anti cancer combinations comprising chemotherapyInfo
- Publication number
- IL318758A IL318758A IL318758A IL31875825A IL318758A IL 318758 A IL318758 A IL 318758A IL 318758 A IL318758 A IL 318758A IL 31875825 A IL31875825 A IL 31875825A IL 318758 A IL318758 A IL 318758A
- Authority
- IL
- Israel
- Prior art keywords
- chemotherapy
- anti cancer
- cancer combinations
- combinations
- cancer
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP22190142 | 2022-08-12 | ||
| PCT/EP2023/072325 WO2024033538A1 (en) | 2022-08-12 | 2023-08-11 | Combination of anticancer agents comprising a bifunctional compound with g12d mutant kras inhibitory activity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL318758A true IL318758A (en) | 2025-04-01 |
Family
ID=83081692
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL318758A IL318758A (en) | 2022-08-12 | 2023-08-11 | Anti cancer combinations comprising chemotherapy |
Country Status (13)
| Country | Link |
|---|---|
| EP (1) | EP4568675A1 (en) |
| JP (1) | JP7733273B2 (en) |
| KR (1) | KR20250044686A (en) |
| CN (1) | CN119584969A (en) |
| AR (1) | AR130192A1 (en) |
| AU (1) | AU2023322690A1 (en) |
| CA (1) | CA3264252A1 (en) |
| CL (1) | CL2025000396A1 (en) |
| CO (1) | CO2025002789A2 (en) |
| IL (1) | IL318758A (en) |
| MX (1) | MX2025001673A (en) |
| TW (1) | TW202410899A (en) |
| WO (1) | WO2024033538A1 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2024337913A1 (en) | 2023-09-08 | 2026-03-26 | Gilead Sciences, Inc. | Pyrimidine-containing polycyclic derivatives as kras g12d modulating compounds |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2015508414A (en) | 2012-01-12 | 2015-03-19 | イエール ユニバーシティ | Compounds and methods for enhanced degradation of target proteins and other polypeptides by E3 ubiquitin ligase |
| CN119591582A (en) | 2014-04-14 | 2025-03-11 | 阿尔维纳斯运营股份有限公司 | Imide-based proteolytic modulators and related methods of use |
| WO2016049565A1 (en) | 2014-09-25 | 2016-03-31 | Araxes Pharma Llc | Compositions and methods for inhibition of ras |
| WO2016049568A1 (en) | 2014-09-25 | 2016-03-31 | Araxes Pharma Llc | Methods and compositions for inhibition of ras |
| US10822312B2 (en) | 2016-03-30 | 2020-11-03 | Araxes Pharma Llc | Substituted quinazoline compounds and methods of use |
| US10646488B2 (en) | 2016-07-13 | 2020-05-12 | Araxes Pharma Llc | Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof |
| JOP20190186A1 (en) | 2017-02-02 | 2019-08-01 | Astellas Pharma Inc | Quinazoline compound |
| CN119569702A (en) | 2018-04-04 | 2025-03-07 | 阿尔维纳斯运营股份有限公司 | Proteolysis regulators and related methods of use |
| CA3102996A1 (en) | 2018-07-20 | 2020-01-23 | Dana-Farber Cancer Institute, Inc. | Degraders that target proteins via keap1 |
| JP2021176820A (en) | 2018-07-31 | 2021-11-11 | アステラス製薬株式会社 | Pharmaceutical composition comprising quinazoline compound as active ingredient |
| WO2021106231A1 (en) | 2019-11-29 | 2021-06-03 | Taiho Pharmaceutical Co., Ltd. | A compound having inhibitory activity against kras g12d mutation |
| EP4132655A1 (en) | 2020-04-06 | 2023-02-15 | Arvinas Operations, Inc. | Compounds and methods for targeted degradation of kras |
| EP4175947A4 (en) | 2020-06-30 | 2024-07-03 | InventisBio Co., Ltd. | QUINAZOLINE COMPOUNDS, PRODUCTION PROCESSES AND USES THEREOF |
| WO2022105855A1 (en) | 2020-11-20 | 2022-05-27 | Jacobio Pharmaceuticals Co., Ltd. | Kras g12d inhibitors |
| US20240140957A1 (en) * | 2021-01-08 | 2024-05-02 | Beigene Switzerland Gmbh | Bridged compounds as kras g12d inhibitor and degrader and the use thereof |
| WO2022148421A1 (en) * | 2021-01-08 | 2022-07-14 | Beigene, Ltd. | Bridged compounds as kras g12d inhibitor and degrader and the use thereof |
| CA3203205A1 (en) | 2021-01-19 | 2022-07-28 | Mandar Ramesh Bhonde | Pharmaceutical combinations of sos1 inhibitors for treating and/or preventing cancer |
| CN116848120B (en) * | 2021-02-15 | 2026-02-13 | 安斯泰来制药株式会社 | Quinazoline compounds used to induce the degradation of G12D mutant KRAS protein |
| PL4293025T3 (en) * | 2021-02-15 | 2026-02-16 | Astellas Pharma Inc. | 4-Aminoquinazoline Composition |
| WO2023119677A1 (en) | 2021-12-24 | 2023-06-29 | Astellas Pharma Inc. | Pharmaceutical composition comprising a quinazoline compound |
-
2023
- 2023-08-11 CA CA3264252A patent/CA3264252A1/en active Pending
- 2023-08-11 AU AU2023322690A patent/AU2023322690A1/en active Pending
- 2023-08-11 KR KR1020257004511A patent/KR20250044686A/en active Pending
- 2023-08-11 JP JP2025501547A patent/JP7733273B2/en active Active
- 2023-08-11 WO PCT/EP2023/072325 patent/WO2024033538A1/en not_active Ceased
- 2023-08-11 AR ARP230102133A patent/AR130192A1/en unknown
- 2023-08-11 IL IL318758A patent/IL318758A/en unknown
- 2023-08-11 CN CN202380057875.2A patent/CN119584969A/en active Pending
- 2023-08-11 TW TW112130324A patent/TW202410899A/en unknown
- 2023-08-11 EP EP23757234.2A patent/EP4568675A1/en active Pending
-
2025
- 2025-02-10 MX MX2025001673A patent/MX2025001673A/en unknown
- 2025-02-11 CL CL2025000396A patent/CL2025000396A1/en unknown
- 2025-03-05 CO CONC2025/0002789A patent/CO2025002789A2/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2023322690A1 (en) | 2025-03-20 |
| AR130192A1 (en) | 2024-11-13 |
| JP7733273B2 (en) | 2025-09-02 |
| MX2025001673A (en) | 2025-03-07 |
| JP2025528008A (en) | 2025-08-26 |
| WO2024033538A1 (en) | 2024-02-15 |
| KR20250044686A (en) | 2025-04-01 |
| CL2025000396A1 (en) | 2025-04-21 |
| CN119584969A (en) | 2025-03-07 |
| CA3264252A1 (en) | 2024-02-15 |
| EP4568675A1 (en) | 2025-06-18 |
| TW202410899A (en) | 2024-03-16 |
| CO2025002789A2 (en) | 2025-04-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3930747A4 (en) | Immunotherapeutic combination for treating cancer | |
| EP3836909A4 (en) | Biomarkers for cancer therapy | |
| EP3892282A4 (en) | Combination for treating cancer | |
| ZA202005847B (en) | Cancer therapy | |
| GB202103080D0 (en) | Cancer biomarkers | |
| GB201818110D0 (en) | Monocytes for cancer targeting | |
| CA3254271A1 (en) | Combination therapies for breast cancer | |
| IL287734A (en) | Tailored hypoimmune nanovesicular delivery systems for cancer tumors | |
| IL291621A (en) | Composite biomarker for cancer therapy | |
| GB202205200D0 (en) | Combination with chemotherapy | |
| IL289006A (en) | Combination cancer immunotherapy | |
| GB202108237D0 (en) | Cancer methods | |
| GB2580963C (en) | Cancer therapies | |
| EP3646869A4 (en) | Chemotherapy for cancer using azabicyclo compound | |
| GB201800733D0 (en) | Cancer | |
| GB201913957D0 (en) | Cancer | |
| GB201912578D0 (en) | Discerning vrain cancer type | |
| GB202301902D0 (en) | Combination therapy for cancer | |
| HUE071473T2 (en) | Miv-818/lenvatinib combination therapy for liver cancer | |
| GB202000739D0 (en) | Cancer | |
| GB202112705D0 (en) | Prostrate cancer biomarkers | |
| GB201914096D0 (en) | Cancer Biomarker | |
| EP4031696A4 (en) | PERSONALIZED CANCER IMMUNOTHERAPY | |
| GB201901991D0 (en) | Cancer | |
| GB202309496D0 (en) | Cancer therapies |